Literature DB >> 6570082

The renal kallikrein-kinin system in spontaneously hypertensive rats.

G Bönner, T Unger, W Rascher, G Speck, D Ganten, F Gross.   

Abstract

In male spontaneously hypertensive rats (SHRSP) of the stroke prone strain (Okamoto) and in normotensive Wistar-Kyoto rats (WKY) urinary kallikrein excretion was investigated at different age and at drug-induced diuresis. In rats of both strains from 7th till 19th week of age urinary kallikrein excretion increased with age. In SHRSP of 7th till 11th week of age kallikrein excretion was higher than in WKY rats, while it was lower in the 48-week-old SHRSP. No correlation was found between urinary kallikrein excretion and systolic blood pressure. In SHRSP and WKY rats a similar daily rhythm of kallikrein excretion in urine was found being high in the early morning and low in the afternoon. Kallikrein excretion correlated significantly with urine volume. The loop diuretic bumetanide (4 and 40 mg/kg) induced diuresis and natriuresis in both strains, however more marked in the WKY rats than in the SHRSP. Urinary kallikrein excretion, however, showed in both strains the same biphasic course with a short lasting increase and a secondary decrease. Thus, in the average urinary kallikrein excretion was not effected by the drug. Prolonged treatment with furosemide over 5 days (125 mg/kg) resulted in an increase in kallikrein excretion in urine, more pronounced in the WKY rats than in the SHRSP. The observed results suggest that renal kallikrein-kinin system is not involved in the development of spontaneous hypertension as a pathogenetic factor, but rather is influenced by other factors like hormone interactions, i.e. mineralocorticoids and catecholamines, as well as renal function and acute changes in urine flow.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6570082     DOI: 10.1007/bf01972335

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  29 in total

1.  Urinary kallikrein excretion in spontaneously hypertensive rats.

Authors:  R G Geller; H S Margolius; J J Pisano; H R Keiser
Journal:  Circ Res       Date:  1975-06       Impact factor: 17.367

2.  Urinary kallikrein in rats bred for susceptibility and resistance to the hypertensive effect of salt and in New Zealand genetically hypertensive rats.

Authors:  O A Carretero; A G Scicli; A Piwonska; J Koch
Journal:  Mayo Clin Proc       Date:  1977-07       Impact factor: 7.616

3.  Sympathetic vascular tone in spontaneous hypertension of rats.

Authors:  A Schömig; R Dietz; W Rascher; J B Lüth; J F Mann; M Schmidt; J Weber
Journal:  Klin Wochenschr       Date:  1978

4.  Urinary kallikrein and changes in endogenous aldosterone in the rat.

Authors:  A Mimran; G Baudin; D Casellas; D Soulas
Journal:  Eur J Clin Invest       Date:  1977-12       Impact factor: 4.686

5.  Altered urinary kallikrein excretion in rats with hypertension.

Authors:  H S Margolius; R Geller; W De Jong; J J Pisano; A Sjoerdsma
Journal:  Circ Res       Date:  1972-03       Impact factor: 17.367

6.  Kallikrein-like activity in the urine of renal hypertensive rats.

Authors:  H R Croxatto; M San Martin
Journal:  Experientia       Date:  1970-11-15

7.  Kallikrein-kinin and renin-angiotensin systems in renovascular hypertension in rats.

Authors:  C P Vío; J S Roblero; H R Croxatto
Journal:  Proc Soc Exp Biol Med       Date:  1980-04

8.  The natriuretic actions of intraarterial acetylcholine and isoprenaline are associated with increased kallikrein excretion in the dog [proceedings].

Authors:  I H Mills; L F Obika
Journal:  J Physiol       Date:  1979-07       Impact factor: 5.182

9.  Plasma angiotensin II: dipsogenic levels and angiotensin-generating capacity of renin.

Authors:  J F Mann; A K Johnson; D Ganten
Journal:  Am J Physiol       Date:  1980-05

10.  Effects on rat urinary kallikrein excretion of bumetanide, bendroflumethiazide and hydralazine.

Authors:  K Nielsen; E Arrigoni-Martelli
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1977-02
View more
  1 in total

1.  Short lasting increase in urinary specific kallikrein activity during long term administration of furosemide.

Authors:  J L Bascands; J P Girolami; C Pecher; G Cabos; J P Moatti; J M Suc; Y Manuel
Journal:  Agents Actions       Date:  1987-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.